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Pulmonary complications after liver transplantation (LT) often cause mortality. This study investigated whether small-for-size
LT increases acute pulmonary injury and whether NIM811 which improves small-for-size liver graft survival attenuates LT-
associated lung injury. Rat livers were reduced to 50% of original size, stored in UW-solution with and without NIM811 (5μM)
for 6h, and implanted into recipients of the same or about twice the donor weight, resulting in half-size (HSG) and quarter-
size grafts (QSG), respectively. Liver injury increased and regeneration was suppressed after QSG transplantation as expected.
NIM811 blunted these alterations >75%. Pulmonary histological alterations were minimal at 5–18h after LT. At 38h, neutrophils
and monocytes/macrophage inﬁltration, alveolar space exudation, alveolar septal thickening, oxidative/nitrosative protein adduct
formation, and alveolar epithelial cell/capillary endothelial apoptosis became overt in the lungs of QSG recipients, but these
alterations were mild in full-size and HSG recipients. Liver pretreatment with NIM811 markedly decreased pulmonary injury
in QSG recipients. Hepatic TNFα and IL-1β mRNAs and pulmonary ICAM-1 expression were markedly higher after QSG
transplantation,whichwerealldecreasedbyNIM811.Together,dysfunctionalsmall-for-sizegraftsproducetoxiccytokines,leading
to lung inﬂammation and injury. NIM811 decreased toxic cytokine formation, thus attenuating pulmonary injury after small-for-
size LT.
1.Introduction
Pulmonary complications including acute lung injury and
acute respiratory distress syndrome frequently occur after
liver transplantation (LT) and contribute signiﬁcantly to
perioperative and postoperative morbidity and mortality [1–
4]. The frequency of pulmonary complications is reported
as high as 75% in some studies [1], and the mortal-
ity rate for acute respiratory distress syndrome reaches
50%–80% [2, 5]. Prolonged cold storage, retrieval pro-
cedures, intraoperative transfusion of plasma-containing
blood products, ischemia/reperfusion- (I/R-) induced graft
injury,proinﬂammatorycytokineandchemokineformation,
leukocyte recruitment and release of neutrophil elastase,
pulmonary endothelial barrier disruption, and vascular
hyperpermeability possibly play critical role in the develop-
ment of posttransplantation acute lung injury [1, 2, 5–8].
Since primary liver graft failure is often associated with
pulmonary injury, prevention and treatment of pulmonary
complications could improve the outcome of LT.
Due to severe shortage of donor organs, partial LT has
increased rapidly in recent years [9–11]. In adult-to-adult
living donor and split LT, small-for-size syndrome occurs
when the ratio of liver graft volume is less than 30–40% of
the standard liver volume of recipient [9, 12]. Such small-
for-size grafts are associated with increased graft injury,
inhibited liver regeneration, poor graft function, more severe
posttransplantation complications, and increased mortality
[9, 12]. Mechanisms of small-for-size liver graft failure
remain unclear but are most likely multifactorial. Energy2 HPB Surgery
supplyiscrucialforcellsurvivalandproliferation.Therefore,
compromised energy supply could lead to liver graft injury
and suppressed regeneration. Our previous studies showed
that free radical production in small-for-size liver grafts
leads to mitochondrial dysfunction [13–15]. Mitochondrial
depolarization occurring in small-for-size liver grafts is
related to opening of high conductance mitochondrial
permeability transition (MPT) pores [16]. MPT pore open-
ing collapses mitochondrial membrane potential, leading
to failure of oxidative phosphorylation. NIM811, a non-
immunosuppressive cyclosporine A derivative, inhibits MPT
pore opening by binding to cyclophilin D, a component of
the pore [17]. In small-for-size liver grafts, NIM811 protects
against mitochondrial depolarization, thus decreasing injury
and improving liver regeneration and functional recovery
[16].
Whether small-for-size LT increases pulmonary com-
plications remains unclear. A previous report showed that
liver splitting procedures cause leukocyte recruitment in the
lung tissue of donor [18]. Rapid onset of acute respiratory
distress syndrome is also observed after major hepatectomy
[19]. Hemodynamic alterations occurring after small-for-
size LT could also lead to pulmonary complications [20, 21].
Moreover, previous studies showed that hepatic I/R pro-
motes remote organ injury, including leukocyte inﬁltration
and parenchymal cell damage in the lung [22]. Accordingly,
this study investigated whether pulmonary complications
occur after small-for-size LT and whether protection against
small-for-size liver graft dysfunction by NIM811 prevents
postoperative acute lung injury.
2. Methods
2.1. Liver Transplantation. Male Lewis rats (170–200g) were
used for orthotopic LT [14, 23]. Brieﬂy, livers were explanted
after ﬂushing in situ with 5mL ice-cold UW cold storage
solution (Barr Laboratories, Pomona, NY) via the portal
vein and removed. In ice-cold UW solution, cuﬀs prepared
from 14-gauge i.v. catheters were placed over the subhepatic
vena cava and the portal vein. Liver mass was reduced ex
vivo to ∼50% of original size by removing the left lateral
lobe, the left portion of the median lobe, and the anterior
and posterior caudate lobes after ligation with 4–0 silk
suture [23]. Explants were stored in UW solution at 0-1◦C
for 6h and rinsed with room-temperature-lactated Ringer’s
solution (Abbott Laboratories, North Chicago, IL) just prior
to implantation. NIM811 (5μM, Novartis Pharma Ltd.,
Switzerland) was added to the storage and rinse solutions.
Reduced-size liver explants were implanted into recipients
of similar (170–200g) or greater body weight (350–420g),
which results in a graft weight/standard liver weight (deﬁned
as 4% body weight) of ∼50% (half-size graft, HSG) and
∼25% (quarter-size graft, QSG), respectively. Unreduced
livers were implanted into recipients of similar body weights
(170–200g) as full-size grafts (FSG). The hepatic artery and
bile duct were reconstructed as described previously [14].
The ratios of graft weight/standard liver weight were not
signiﬁcantlydiﬀerentbetweenQSGwithorwithoutNIM811
treatment (P>0.1b yS t u d e n t s ’t-test). All animals were
given humane care in compliance with institutional guide-
lines using protocols approved by the Institutional Animal
Care and Use Committee.
2.2. Serum Alanine Aminotransferase (ALT). To access liver
graft injury, serum ALT was measured from blood samples
collected from the vena cava at 38h after implantation using
analytical kits from Sigma Chemical (St. Louis, MO). To
adjust for graft size and recipient blood volume, serum ALT
was normalized by multiplying by the recipient’s standard
blood volume (6.4% of body weight) and dividing by graft
weight [24].
2.3. Pulmonary and Hepatic Histology. Under pentobarbital
(50mg/kg, i.p.) anesthesia at various times after implanta-
tion (5, 18, and 38h), the lung and liver were harvested and
ﬁxed with 4% paraformaldehyde in Dulbecco’s phosphate
buﬀeredsaline(InvitrogenCorp.GrandIsland,NY)[25,26],
imbedded in paraﬃn and processed for histology. In sections
stained with hematoxylin and eosin (H&E), lung and liver
images were acquired using a Universal Imaging Image-1/AT
image acquisition and analysis system (West Chester, PA)
incorporating an Axioskop 50 microscope (Carl Zeiss, Inc.,
Thornwood, NY) and using 20x and 10x objective lenses,
respectively. Alveolar septal wall thickness was quantiﬁed by
image analysis of 5 randomly selected alveolar septa per ﬁeld
in 10 randomly selected ﬁelds per slide using an IPlab 3.7v
software (BD Biosciences, Rockville, MD). Relative alveolar
septal thickness was expressed as the ratios between the
average thicknesses of diﬀerent transplantation groups to
the sham-operation group. Liver necrosis was quantiﬁed by
image analysis of 10 randomly selected ﬁelds per liver in a
blinded manner using the same software and calculated by
dividing the necrotic areas by the total cellular area [26].
2.4. Immunohistochemical Staining for 5-Bromo-2 -Deox-
yuridine, Myeloperoxidase, ED1, and Intracellular Adhe-
sion Molecule-1. To assess liver regeneration, 5-bromo-
2 -deoxyuridine (BrdU, 100mg/kg i.p.) was injected 1h
prior to liver harvesting to detect cells synthesizing DNA.
BrdU incorporation in liver sections was determined by
immunohistochemical staining as described elsewhere [27,
28]. For immunohistochemistry of leukocytes and adhesion
molecules in the lung tissue, pulmonary sections were
deparaﬃnized with xylene (Mallinckrodt Baker, Paris, Ken-
tucky) and taken through a graded series of alcohol/water
mixturestorehydratethetissue.Tostainformyeloperoxidase
(MPO), an indicator of neutrophil inﬁltration, lung sections
were immersed in 10mM citrate acid (pH 6), heated in
microwave for antigen retrieval, and then exposed to rabbit
anti-MPO polyclonal antibodies (DAKO Corp., Carpinteria,
CA) at a concentration of 1:200 in 0.1M phosphate buﬀer-
0.5% Tween 20 for 30min at room temperature followed by
a 20min incubation with peroxidase-conjugated anti-rabbit
IgG1 antibody (DAKO Corp., Carpinteria, CA) at room
temperature. 3,3 -Diaminobenzidine chromagen was then
added as the peroxidase substrate. After the immunostainingHPB Surgery 3
procedure, a light counterstain of Meyer’s hematoxylin
was then applied. MPO-positive cells were counted in 10
random ﬁelds per slide in a blind manner using a 40x
o bjecti v ele n s[29]. Immunohistochemistry of ED1, amarker
of monocytes/macrophages, was performed using speciﬁc
antibody (Serotek, Raleigh, NC) at a dilution of 1:150
for 30min at room temperature. To stain for intracellular
adhesion molecule 1 (ICAM-1) in the lungs, slides were
treated in microwave as described previously for antigen
retrieval and then exposed to rabbit anti-ICAM-1 polyclonal
antibodies (BD Biosciences Pharmingen, San Diego, CA) at
a concentration of 1:200 overnight at 4◦C.
2.5. Immunoblotting. Liver tissue was homogenized in 0.1M
phosphate buﬀer (pH 7.2) containing 0.1% SDS, 1% IGEPal,
1%protease,and1%phosphataseinhibitorcocktails(Sigma,
St. Louis, MO) and centrifuged at 14,000×gf o r1 5 m i n
at 4◦C. Aliquots of supernatant (40μg of protein) were
separated on NuPAGE 4–12% Bis-Tris gels, transferred
onto nitrocellulose membranes, and immunoblotted with
primary antibodies speciﬁc for proliferating cell nuclear
antigen (PCNA; Dako, Glostrub, Denmark) at 1:1000 and
actin (ICN, Costa Mesa, CA) at 1:3000 over night at
4◦C. Horseradish peroxidase-conjugated secondary antibod-
ies were applied, and detection was by chemiluminescence
(Pierce Biotec., Rockford, IL).
2.6. Detection of Interleukin-1β and Tumor Necrosis Factor-
α mRNAs by Quantitative Real-Time PCR. Total RNA was
isolated from liver tissue with Trizol (Invitrogen, Grand
Island, NY). Single stranded cDNAs were synthesized from
RNA (2mg) from liver tissue using a Bio-Rad iScript
cDNA Synthesis kit (Bio-Rad, Hercules, CA) [30]. The
primer sequences are listed in Table 1. qPCR was conducted
using a CFX96 Real-Time PCR Detection System (Bio-Rad,
Hercules, CA). The abundance of mRNAs was normalized
against hypoxanthine phospho-ribosyl-transferase (HPRT),
a house-keeping gene, using the ΔΔCt method.
2.7. Statistical Analysis. Groups were compared using
ANOVA plus a Student-Newman-Keuls post hoc test. Data
shown are means ± S.E.M. Group sizes were 4 livers in
each group for all parameters, as indicated in Section 3 and
corresponding ﬁgure legends. Diﬀerences were considered
signiﬁcant at P<0.05.
3. Results
3.1. Increased Liver Injury and Suppressed Regeneration of
Small-for-Size Liver Grafts: Reversal by NIM811. Previously,
we reported that all recipients of FSG survived after trans-
plantation [14]. Survival was decreased slightly to 80%
after transplantation of HSG and markedly to 30% in QSG
recipients [14]. Inhibition of the MPT by NIM811 decreased
injury,improvedliverregeneration,andincreasedsurvivalof
small-for-size liver grafts from 30% to 81% [16]. Consistent
with the early work, in the present study, no pathological
changes were observed in liver tissue at 5h (data not shown)
Table 1: Primers for Real-Time PCR.
mRNAs Primers
IL-1β Forward: 5 -AGCAGCTTTCGACAGTGAGGAGAA-3 
Reverse: 5 -TCTCCACAGCCACAATGAGTGTGACA-3 
TNF-α Forward: 5 -CAGACCCTCACACTCAGATCATCTT-3 
Reverse: 5 -CAGAGCAATGACTCCAAAGTAGACCT-3 
HPRT Forward: 5 -TCGAAGTGTTGGATACAGGCCAGA-3 
Reverse: 5 -TACTGGCCACATCAACAGGACTCT-3 
IL-1β: interleukin-1β;T N F - α: tumor necrosis factor; HPRT: hypoxanthine
phospho-ribosyl-transferase.
and 38h after sham operation (Figure 1(a)), and necrosis
was minimal in FSG and HSG. At 5h after transplantation,
necrosis was barely detectable in QSG (data not shown).
By contrast, necrosis increased at 38h after implantation
of QSG, mainly in periportal and midzonal regions of liver
lobules. NIM811 decreased necrosis in QSG (n = 4p e r
group). Serum ALT (Figure 1(c)) was ∼0.09U/g liver before
transplantation. ALT increased at 5h after transplantation of
QSG, peaked at about 18h, and then remained at high levels
(not shown). At 38h after implantation, ALT was ∼14U/g in
ratsreceivingQSGbutwasonly0.3U/gliverand1.3U/gliver
in rats receiving FSG and HSG, respectively, indicating more
severe injury in QSG. NIM811 decreased ALT to 2.9U/g in
QSG recipients (n = 4p e rg r o u p ) .
Liver regeneration was evaluated by BrdU incorporation
(Figure 1(b)) and expression of PCNA (Figure 1(d)). BrdU-
positive cells were barely detectable at 5h (not shown)
and 38h after sham-operation and in FSG (Figure 1(b)).
In HSG, BrdU labeling was undetectable at 5h, increased
slightly after 18h (not shown), and increased sharply at
38h (Figure 1(b)). Proliferating cells were predominantly
hepatocytes[13].Incontrast,BrdU-positivecellswererarein
QSG at all time points (n = 4 per group). PCNA was barely
detectable in sham-operated livers and FSG but increased
substantially in HSG (∼160-fold) at 38h, consistent with cell
proliferation. PCNA expression increased only ∼4.6-fold in
QSG (n = 4 per group). These results show suppression of
cell proliferation in QSG, which NIM811 largely reversed.
3.2. Pulmonary Leukocyte Inﬁltration and Injury Is Greater
after Small-for-Size Liver Transplantation. Pulmonary
leukocyte inﬁltration and injury were evaluated at 5, 18,
and 38h after LT. At 5h after transplantation of QSG, very
mild perivascular edema was observed. However, alveolar
septal thickness was not signiﬁcantly increased (Figures 2(b)
and 2(i)). ED1-positive monocytes/macrophages increased
slightly (Figures 2(f) and 2(j)), but neutrophils were not
increased (Figure 2(k)). At 18h after transplantation, the
alveolar septa were slightly thickened compared to 5h, but
leukocyte inﬁltration remained at low levels (Figures 2(c),
2(g), 2(i), 2(j), and 2(k)). At 38h after transplantation of
QSG, alveolar septa were markedly thickened (4.1-fold)
with increased cellularity (Figures 2(d) and 2(i)). Numerous
leukocytes, including neutrophils and mononuclear cells,
were seen in the peribonchial spaces, the lumina of blood
vessels, and the perivascular as well as intra-alveolar space.4 HPB Surgery
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Figure 1: NIM811 protects against graft injury and promotes liver regeneration after transplantation of small-for-size liver grafts. Full-size
andreduced-sizeratliversweretransplanted,asdescribedinSection 2.Insomeexperiments,NIM811(NIM,5μM) was added to the storage
and poststorage lactated Ringer’s rinse solutions. In (a) and (b), liver grafts were harvested at 38h after transplantation for H&E staining
((a), bar is 100μm) or BrdU immunohistochemistry ((b), bar is 50μm). Representative images are shown. Arrows identify necrotic areas.
Panels are as follow: 1st row, liver from a sham-operated rat; 2nd row, FSG (100%); 3rd row, HSG (50%); 4th row, QSG (25%); 5th row,
QSG treated with NIM811. In (c), blood samples were collected at 38h after transplantation for ALT measurement. In (d), proliferating
cell nuclear antigen (PCNA) expression in liver tissue was detected by immunoblotting and quantiﬁed by densitometry. Values are means ±
S.E.M. Group sizes were 4 per group: (a) P<0.05 versus sham operation; (b) P<0.05 versus FSG (100%); (c) P<0.05 versus HSG (50%);
(d) P<0.05 versus QSG (25%).
At 38h, ED1-positive cells (monocytes/macrophages)
increased ∼6.5-fold and MPO-positive cells (neutrophils)
increased ∼47-fold (Figures 2(j) and 2(k)) (n = 4p e r
group for all parameters). Together, these ﬁndings show that
lung pathological changes became marked at ∼38h after
transplantation of small-for-size grafts. At earlier times after
QSG transplantation, inﬁltration was slight and composed
predominantly of mononuclear cells.
Lung injury was compared among groups at 38h after
transplantation. After transplantation of FSG, alveolar septaHPB Surgery 5
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Figure 2: Time course of pulmonary histopathological changes after transplantation of small-for-size liver grafts. In (a)–(d), lungs were
harvested at 5, 18, and 38h after transplantation of QSG. Lung sections were stained with H&E. In (e)–(h), representative images of ED1
staining (n = 4 per group) are shown. In (i), alveolar septal thickness was quantiﬁed by image analysis of 5 random alveolar septa per image
and10randomimagesperslideusingIPlab3.7vsoftware.Relativealveolarseptalthicknesswasexpressedastheratiobetweenthethicknesses
of diﬀerent transplantation groups to the sham-operation group. In (j) and (k), ED1 (j) and myeloperoxidase (MPO, (k)) positive cells per
high power ﬁeld (hpf) were counted in 10 random ﬁelds using a 40x objective lens in a blinded manner. Values are means ± S.E.M. Group
sizes are 4 per group: ∗P<0.05 and ∗∗P<0.01 versus 0h.
were not thickened, and neutrophils were not increased,
but monocytes/macrophages increased ∼3-fold (Figure 3).
After transplantation of HSG, alveolar septa thickened
slightly (1.9-fold), and monocyte/macrophages increased
∼3-fold, but neutrophils were not increased. Overall, after
transplantation of QSG, alveolar septal thickening, increased
cellularity, monocyte/macrophage, and neutrophil seques-
trationweresubstantiallymoreseverecomparedtorecipients
o fF S Ga n dH S G( Figure 3)( n = 4p e rg r o u p ) .
3.3. NIM811 Attenuates Lung Injury after Transplantation of
Small-for-Size Liver Grafts. Since NIM811 decreased hepatic
injury after small-for-size LT, we examined the eﬀects of
NIM811 on lung injury. Compared to vehicle, NIM811
decreased alveolar septal thickening by 52%, mono-
cyte/macrophage inﬁltration by 44% and neutrophil inﬁl-
tration by 51% in QSG recipients (Figure 3)( n = 4p e r
group). Overall, alveolar septal thickening and mono-
cyte/macrophage inﬁltration after NIM811 treatment of6 HPB Surgery
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Figure 3: NIM811 decreases lung inﬂammation after small-for-size liver transplantation. Full-size and reduced-size rat livers were
transplanted, as described in Section 2. Lungs were harvested 38h after transplantation. Alveolar septal thickness (a) was quantiﬁed by
image analysis of 5 random alveolar septa per image from 10 random images per H&E-stained slide using a IPlab 3.7v software. ED1 positive
cells (b) and myeloperoxidase (MPO) positive cells (c) after immunohistochemical staining were counted in 10 random ﬁelds per slide using
a 40x objective lens. Sham: lungs from sham-operated rats; 100%: lungs from FSG recipients; 50%: lungs from HSG recipients; 25%: lungs
from QSG recipients; 25% + NIM: lungs from recipients of QSG treated with NIM811. Values are means ± S.E.M. Group sizes were 4 per
group: (a) P<0.05 versus sham operation; (b) P<0.05 versus FSG (100%); (c) P<0.05 versus HSG (50%); (d) P<0.05 versus QSG (25%).
QSG returned to levels close to those observed after
transplantation of FSG and HSG. Neutrophil inﬁltration,
althoughdiminished,remainedincreasedrelativetoFSGand
HSG.
3.4. Oxidative/Nitrosative Stress and Apoptosis after
Transplantation of Small-for-Size Liver Grafts: Protection
by NIM811. Previous studies show that oxidative and
nitrosative stresses occur in pulmonary injury after hepatic
I/R [22, 31]. Inﬁltrating leukocytes can produce reactive
oxygen and nitrogen species, leading to oxidative and
nitrosative stresses and cell death in the lung. Oxidative and
nitrosative stresses were evaluated by 4-hydroxynonenal
and 3-nitrotyrosine adduct formation, respectively
(Figure 4)( n = 4p e rg r o u p )[ 32]. 4-Hydroxynonenal
and 3-nitrotyrosine adducts were barely detectable
in the lung tissue after sham operation and full-size
LT (Figure 4). At 38h after implantation of HSG, 4-
hydroxynonenal and 3-nitrotyrosine adducts in the lung
increased slightly. By contrast, 4-hydroxynonenal and
3-nitrotyrosine immunostaining became marked after
transplantation of QSG (Figure 4). Staining occurred in
some leukocytes, vascular endothelial cells and alveolar
epithelial cells. NIM811 partially decreased hydroxynonenal
and nitrotyrosine protein adducts in the lung after
transplantation of QSG (Figure 4).
Pulmonary apoptosis was revealed by TUNEL staining.
TUNEL-positive cells (shown by red nuclear staining) were
rare in pulmonary tissue after sham operation and full-size
LT. TUNEL-positive cells increased slightly after transplan-
tation of HSG and markedly after transplantation of QSGHPB Surgery 7
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Figure 4: Increased pulmonary oxidative and nitrosative adduct formation after transplantation of small-for-size liver grafts: Prevention by
NIM811. Lungs were harvested 38h after transplantation. Representative images of pulmonary slides after immunohistochemical staining
for 4-hydroxynonenal (left column) and 3-nitrotyrosine (right column) are shown. Panels are as follow: 1st row, lung from a sham-operated
rat; 2nd row, lung from a FSG recipient (100%); 3rd row, lung from a HSG recipient (50%); 4th row, lung from a QSG recipient (25%); 5th
row, lung from a recipient of a QSG treated with NIM811. Group sizes were 4 per group.8 HPB Surgery
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Figure 5: NIM811 protects against apoptosis in the lung after transplantation of small-for-size liver grafts. Lungs were harvested 38h after
transplantation. Representative images of pulmonary slides (n = 4 per group) after TUNEL staining are shown in (a)–(d). TUNEL-positive
cells were counted in 10 random ﬁelds per slide using a 20x objective lens (e). Sham: lungs from sham-operated rats; 100%: lungs from
FSG recipients; 50%: lungs from HSG recipient; 25%: lungs from QSG recipients; 25% + NIM: lungs from recipients of QSG treated with
NIM811. Values are means ± S.E.M. Group sizes were 4 per group. (a) P<0.05 versus sham operation; (b) P<0.05 versus FSG (100%); (c)
P<0.05 versus HSG (50%); (d) P<0.05 versus QSG (25%).
(Figure 5). Apoptotic cells were primarily vascular endothe-
lial cells, and/or alveolar epithelial cells. Pretreatment of liver
grafts with NIM811 decreased apoptosis in the lung after
transplantation of QSG (Figure 5)( n = 4p e rg r o u p ) .
3.5. NIM811 Decreased Toxic Cytokine Formation in Small-
for-Size Liver Grafts. Failing liver grafts possibly produce
toxic, inﬂammatory cytokines, resulting in inﬂammation in
remote organs. Accordingly, we measured hepatic cytokine
expression after transplantation (n = 4p e rg r o u pf o ra l l
cytokines). Tumor necrosis factor alpha (TNFα) mRNA did
not increase in FSG and increased only slightly (1.7-fold)
in HSG (Figure 5(a)). By contrast after transplantation of
QSG, TNFα mRNA increased ∼4-fold. NIM811 treatment of
QSG decreased TNFα mRNA by 43% (Figure 6(a)). Similar
changes occurred for interleukin-1β (IL-1β). IL-1β mRNA
increased slightly (∼2.5-fold) in both FSG and HSF but
increased 8.1-fold in QSG (Figure 6(b)). NIM811 blunted
the increase of IL-1β mRNA in QSG by 32%.
3.6. NIM811 Decreased Adhesion Molecule Expression in the
Lung after Transplantation of Small-for-Size Liver Grafts.
Proinﬂammatory cytokines released from the failing grafts
may promote adhesion molecule expression in remote
organs, thus promoting leukocyte inﬁltration and inﬂamma-
tion in these organs. Accordingly, we investigated intercel-
lular adhesion molecule 1 (ICAM-1) expression in the lung
(n = 4 per group). ICAM-1 was barely detectable in lungs
of sham-operated rats and recipients of FSG (Figures 6(c)
and 6(d)). ICAM-1 expression increased slightly after trans-
plantation of HSG and substantially after transplantation of
QSG(Figures6(e)and6(f)).ICAM-1expressionincreasedin
vascular endothelial cells and alveolar epithelial cells (Figure
6), as well as bronchial epithelial cells (not shown). NIM811HPB Surgery 9
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Figure 6: Hepatic toxic cytokine formation and pulmonary expression of adhesion molecules increased after transplantation of small-for-
size liver grafts: Reversal by NIM811. Liver grafts and lungs were harvested at 38h after transplantation. TNFα (a) and IL-1β (b) mRNAs
were detected by real-time PCR. Values are means ± S.E.M. Group sizes were 4 per group. (a) P<0.05 versus sham operation; (b) P<0.05
versus FSG (100%); (c) P<0.05 versus HSG (50%); (d) P<0.05 versus QSG (25%). In (c)–(g) pulmonary ICAM-1 expression was detected
immunohistochemically, and representative images are shown (n = 4 per group): (c) lung from a sham-operated rat; (d) lung from a FSG
recipient (100%); (e) lung from HSG graft recipient (50%); (f) lung from QSG recipient (25%); (g) lung from a recipient of QSG pretreated
with NIM811.10 HPB Surgery
bluntedpulmonaryIACM-1expressionaftertransplantation
of QSG (Figure 6(g)).
4. Discussion
4.1.AcuteLungInjuryIncreasesafterTransplantationofSmall-
for-Size Liver Grafts. Pulmonary complications are severe
and life-threatening conditions that adversely aﬀect the
clinical outcomes of LT, leading to high mortality [1, 3, 5].
Many factors during transplantation may cause pulmonary
complications. LT often involves substantial blood loss,
necessitating blood transfusion, and large ﬂuid shifts, which
can lead to pulmonary edema [1, 3, 5]. Liver I/R injury
can cause damage to remote organs, such as lung and
kidney [22]. Prolonged cold storage aggravates damage to
donor livers and leads to acute lung injury after LT [6].
Pulmonary complications also occur frequently in patients
with fulminant hepatic failure [33], suggesting interactions
of liver and pulmonary functions. Clearly, prevention of
pulmonary complications is crucial for increasing survival
after LT.
With more frequent application of partial LT, preven-
tion and treatment of the small-for-size syndrome become
increasingly important for improving the clinical outcomes.
Therefore, in this study we investigated whether transplan-
tation of small-for-size liver grafts increases the risk of
acute lung injury after transplantation. After transplanta-
tion of FSG, lung injury was minimal (Figure 3). After
transplantation of HSF, pathological changes in the lung
were modest (Figure 3). In contrast, transplantation of QSG
resulted in overt pathological changes in the lung, includ-
ing inﬁltration of inﬂammatory cells, increased alveolar
septal cellularity and thickness, exudates in alveoli, oxida-
tive/nitrosative adduct formation, and vascular endothe-
lial/pulmonary epithelial cell death (Figures 2, 3, 4,a n d
5). These results indicate that small-for-size LT increases
lung injury. Interestingly, lung injury occurred at a relatively
late stage after transplantation (38h), at a time point when
mortality occurs [14]. These observations indicate that
pulmonary complications are, at least in part, responsible
for high mortality after transplantation of small-for-size liver
grafts.
4.2. Protection of Liver Mitochondria by NIM811 Prevents
Pulmonary Complications after Transplantation of Small-for-
Size Liver Grafts. Lung edema could occur due to massive
blood transfusion or ﬂuid shift. Transfusion-related lung
edema usually occurs early after transplantation. In this
study, all recipients received similar amounts of lactated
Ringer’s solution during transplantation. In addition, no
overt edema was detected at 5–18h after transplantation in
any groups. Therefore, the pulmonary injury observed in
this study is unlikely due to transfusion. By contrast, lung
injury occurred at a later stage (38h) after transplantation
and predominantly in the recipients of small-for-size liver
grafts. Previous studies showed that in these small grafts,
mitochondrial dysfunction occurs, leading to decreased ATP
production, more severe graft injury, suppressed regenera-
tion, and poorer liver function [13, 14, 16]. Mitochondrial
dysfunction in these small-for-size grafts is not due to
upregulation of uncoupling proteins but is related to onset
of the MPT [16]. Opening of nonselective, highly conductive
permeability transition pores in the mitochondrial inner
membrane causes onset of the MPT [34]. MPT onset
collapses the mitochondrial membrane potential, uncouples
oxidative phosphorylation, and leads to necrotic cell death
from ATP depletion [35, 37, 38]. Moreover, the MPT
causes release of cytochrome c from the intermembrane
space, which triggers activation of caspases and apoptosis
[35, 36]. Growing evidence supports a critical role of the
MPT in cell necrosis and apoptosis in I/R injury [37, 38].
NIM811, a MPT inhibitor, prevented hepatic mitochondrial
dysfunction, decreased injury, and improved regeneration
of small-for-size liver grafts [16]. This treatment increases
survival after small-for-size liver grafts from 30% to 81%
[16].Here,weshowthatNIM811alsosubstantiallydecreases
lung inﬂammation and injury after transplantation of QSG.
Since NIM811 was added only to the cold storage solution
and the poststorage rinse solution, actions of NIM811 are
predominantly in the liver. Therefore, protection by NIM811
on the lung is most likely secondary to decreases in liver
injury and improvement of liver graft function. A direct
eﬀect of NIM811 on lung appears unlikely, since only a
small amount of NIM811 in the vasculature of quarter-
size grafts enters the circulation and is distributed to other
organs of the recipient. Studies will be performed in the
future to determine pulmonary NIM811 concentrations at
various times after transplantation of small-for-size grafts
andtoassesswhethertreatmentofrecipientswithNIM811at
similarlevelscouldprotectagainstpulmonaryinﬂammation.
4.3. Role of Toxic Cytokine Release from Small-for-Size Liver
Grafts in Lung Injury. How small-for-size liver grafts cause
lung injury remains unclear. We tested the hypothesis that
toxiccytokinesreleasedfromfailingsmall-for-sizelivergrafts
result in lung injury. Leukocytes increased markedly in the
lungs of QSG recipients but only mildly after transplantation
o fF S Ga n dH S Gw h i c hd on o tf a i l( Figure 3). Liver I/R
injury can cause inﬂammatory responses in remote organs,
including the lung [22]. Pulmonary neutrophil inﬁltration
and release of elastase result in acute lung injury after LT,
and this injury can be attenuated by an elastase inhibitor
[39]. Prolonged cold storage increases hepatic production
of proinﬂammatory cytokines TNFα and IL-1β, resulting in
pulmonary NFκ-B activation and subsequent inﬂammatory
responsesandacutelunginjury[6].Apreviousstudyshowed
that transplantation of 60%-liver grafts does not change liver
TNFα and IL-1β [25]. In the present study after transplan-
tation of FSG, TNFα and IL-1β mRNA did not increase in
the liver grafts, most likely due to the short cold storage time
(Figure 6). Moreover, hepatic TNFα and IL-1β expression
increased only slightly in HSG. By contrast, expression of
these cytokines increased markedly in QSG (Figure 6). In
parallel, pulmonary expression of ICAM-1 and leukocyte
recruitment increased only modestly in the lungs of HSG
recipients but substantially in QSG recipients (Figures 3 and
6). NIM811, which prevents injury to QSG, reduced hepaticHPB Surgery 11
TNFα and IL-1β expression, pulmonary ICAM-1 expression,
and leukocyte recruitment. These results are consistent with
the conclusion that failing small-for-size grafts produce toxic
cytokines that promote inﬂammation and injury in the lung.
Surgical trauma during liver splitting also increases
leukocyte sequestration into donor lungs [18]. Partial LT
requires more complicated surgical procedures, and organ
manipulation during liver harvest increases graft injury and
activates Kupﬀer cells, which are the major resources of toxic
cytokines in the liver [40–43]. Destruction of Kupﬀer cells
with gadolinium chloride prevents pulmonary injury after
hepatic I/R [44]. However, in this study HSG and QSG were
exposed to virtually identical surgical procedures. Nonethe-
less, toxic cytokine formation was substantially higher in
QSG than that in HSG after transplantation. Therefore,
higher toxic cytokine production in QSG is unlikely to be
solely due to surgical trauma. Liver injury was more severe in
small-for-sizelivergrafts,whichmaystimulateinﬂammatory
responses and toxic cytokine formation. Diminishing small-
for-size graft injury by NIM811 may then decrease subse-
quent toxic cytokine formation.
ROS production increases markedly in small-for-size
liver grafts [14]. ROS trigger opening of MPT pores [36, 45–
47], and uncoupling of oxidative phosphorylation caused
by the MPT further increases oxidative stress [45, 48], thus
causing a vicious cycle. ROS are well known triggers of toxic
cytokine formation [49, 50]. Therefore, breaking the vicious
cycle of ROS production by MIN811 could also decrease
toxic cytokine formation. In addition to proinﬂammatory
cytokine production, poor liver function causes hyper-
bilirubinemia. Although bilirubin has antioxidant properties
[51], bilirubin also causes mitochondrial toxicity and has
ad e t r i m e n t a le ﬀect on lung surfactant surface tension
properties [52–54]. Hyperbilirubinemia due to small-for-
size LT may also contribute, in part, to lung injury in the
recipients. It seems likely that these detrimental factors act
together to promote lung injury.
5. Conclusions
Takentogether,thisstudyshowsthatacutelunginjuryoccurs
after transplantation of small-for-size liver grafts, possibly
due to increased proinﬂammatory cytokine formation from
injured and/or failing grafts with subsequent inﬂammatory
changes in the lung. Protection of the small-for-size grafts
by NIM811 diminishes this lung injury. These results also
suggest that anti-inﬂammatory treatment can be eﬀective in
prevention of lung injury, thus improving the outcome of
small-for-size LT.
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